About Dr. Liu Zhengguo
Dr. Liu Zhengguo is a senior neurologist at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of China's foremost academic centres for Parkinson's disease, movement disorders, and functional neurology. He is a nationally recognised leader in deep brain stimulation (DBS) therapy, with particular expertise in post-operative programming optimisation, cognitive preservation strategies, and the management of complex long-term DBS cases. Dr. Liu's practice is defined by the philosophy that DBS surgery is the beginning of treatment, not the end — and that the quality of long-term programming determines outcomes as much as the precision of electrode placement. His team at Ruijin Hospital has established one of China's most comprehensive DBS programming centres, integrating neurological, neuropsychological, and rehabilitation expertise into a unified post-operative care pathway for Parkinson's disease patients.
Case Overview
Professor Michael Hartley, a 52-year-old British university professor and doctoral supervisor based in Shanghai, presented with a 15-year history of young-onset Parkinson's disease and a two-year history of bilateral subthalamic nucleus deep brain stimulation (STN-DBS). He had undergone DBS implantation at age 50 for medically refractory dyskinesia and motor fluctuations, with excellent initial results. Over the preceding six months, he had developed progressive gait freezing, speech hesitancy, and executive function decline — with MoCA falling from 24 to 22 — raising concern for stimulation-induced cognitive side effects superimposed on disease progression. Dr. Liu Zhengguo performed systematic monopolar review and identified that left Contact 2 stimulation was producing speech arrest and muscle rigidity consistent with current spread to the internal capsule. He redesigned the stimulation programme using directional current steering with interleaving stimulation (Contact 0–1 at 80 Hz / Contact 1–2 at 130 Hz, left side), reduced right-sided frequency to 80 Hz for axial symptom control, and reduced levodopa dose by 25%. At three-month follow-up, UPDRS-III improved from 45 to 18, dyskinesia resolved completely, FOG-Q score improved by 50%, and MoCA recovered to 25. The professor returned to lecturing and resumed academic writing.
Patient Background
- Name / Nationality: Professor Michael Hartley (pseudonym) — British; university professor and doctoral supervisor based in Shanghai
- Age / Sex: 52-year-old male
- Parkinson's History: Young-onset PD diagnosed at age 45; initial presentation right upper limb resting tremor; 15-year disease duration
- Medication History: Levodopa/benserazide, pramipexole, entacapone — progressive dose escalation with diminishing efficacy and severe peak-dose dyskinesia
- DBS History: Bilateral STN-DBS implanted 2 years prior for medically refractory dyskinesia and motor fluctuations; excellent initial response
- Current Complaint: Progressive gait freezing, speech hesitancy, and executive function decline over 6 months; patient reports “thinking has slowed down”
- Non-motor Symptoms: Severe constipation; REM sleep behaviour disorder (RBD); mild depression
Clinical and Neuropsychological Assessment
Motor Evaluation
- UPDRS-III (off-medication): 45 — severe motor impairment
- Dyskinesia: Peak-dose dyskinesia involving head, face, and bilateral upper limbs — severely impairing writing and eating
- Gait: Freezing of gait (FOG) on initiation and turning; festination present
- Current DBS parameters: Bilateral Contact 2–, 3.0V, 60μs, 130Hz — standard high-frequency monopolar configuration
Cognitive and Psychiatric Assessment
- MoCA: 22/30 (declined from 24 at DBS implantation) — primary deficits in executive function (Trail Making Test B impaired) and delayed recall
- MMSE: 26/30
- Patient report: “I can no longer write papers at my previous speed. My thoughts feel foggy after the stimulator is on.”
Imaging
- Brain MRI: No significant cortical atrophy; DBS electrode positions confirmed in STN dorsolateral motor territory bilaterally — anatomically correct placement
- Implication: Cognitive decline not attributable to electrode misplacement or structural disease progression — stimulation parameter optimisation is the primary intervention
Clinical Decision Making
Two competing hypotheses explained the patient's deterioration: disease progression with natural cognitive decline in long-standing PD; or stimulation-induced side effects from current spread beyond the STN motor territory into the internal capsule (causing rigidity and speech arrest) or the ventromedial limbic STN (impairing executive function and verbal fluency).
The distinction is critical — disease progression cannot be reversed by reprogramming, but stimulation-induced side effects can. Systematic monopolar contact review was the diagnostic tool to differentiate them.
Dr. Liu Zhengguo's programming strategy: The first question in any DBS patient with new cognitive symptoms is always: is this the disease, or is this the stimulator? If it is the stimulator, we can fix it. If it is the disease, we manage it differently. The monopolar review is our diagnostic test. We stimulate each contact individually and watch what happens — to the motor symptoms, to the speech, to the cognition. When Contact 2 on the left produces speech arrest and rigidity, that tells us the current is reaching the internal capsule. The solution is not to reduce the voltage globally — that will worsen the motor control. The solution is to redirect the current away from the internal capsule and toward the dorsolateral motor STN. That is what directional programming gives us.
Precision DBS Reprogramming
Phase 1 — Systematic Monopolar Contact Review
Each contact tested individually at incrementally increasing voltages while monitoring motor response, speech fluency, and side effect threshold:
- Left Contact 2 (active): At 3.0V — speech arrest and upper limb rigidity at therapeutic voltage; current spread to internal capsule confirmed. Contact 2 deactivated.
- Left Contact 0 (dorsal): Good motor benefit at 2.8V; no speech or cognitive side effects — current confined to dorsolateral motor STN
- Left Contact 1 (intermediate): Supplementary motor benefit at 2.5V; no side effects
- Right side: Contact 1–2 configuration maintained; frequency reduction from 130Hz to 80Hz trialled — patient reported subjective improvement in gait initiation within 30 minutes
Phase 2 — Directional Current Steering with Interleaving Stimulation
Left hemisphere programme: Interleaving stimulation combining two pulse trains delivered in alternating sequence — Contact 0–1+ at 2.8V / 60μs / 80Hz, and Contact 1–2+ at 2.5V / 60μs / 130Hz. This configuration sculpts the electrical field to cover the dorsolateral motor STN while avoiding the ventromedial limbic territory and the internal capsule — achieving motor benefit without cognitive or speech side effects.
Right hemisphere programme: Contact 1–2+, 2.6V, 60μs, 80Hz — low-frequency stimulation selected for axial symptom predominance (gait freezing, postural instability). Evidence supports 60–80Hz stimulation for axial symptoms in PD, with less interference with executive function networks than 130Hz.
Dr. Liu's programming note: Interleaving stimulation is not a technical trick. It is a biological strategy. The STN is not a homogeneous nucleus — it has a dorsolateral motor zone, a central associative zone, and a ventromedial limbic zone. Standard monopolar stimulation at 130Hz floods all three zones simultaneously. Interleaving with directional contacts allows us to deliver different frequencies and voltages to different anatomical subregions in the same nucleus. We are not just turning a dial. We are sculpting an electrical field around a three-dimensional anatomical target. That requires understanding the anatomy, the patient's symptom profile, and the physics of current spread simultaneously.
Phase 3 — Drug-Stimulation Balance Optimisation
Levodopa reduction: Levodopa/benserazide reduced from 1 tablet four times daily to 0.75 tablets four times daily — a 25% dose reduction. The primary advantage of STN-DBS over GPi-DBS is its capacity to enable substantial levodopa reduction. Excess levodopa in a well-stimulated STN patient contributes to cognitive fog, impulse control symptoms, and dyskinesia. Reducing the levodopa dose — while maintaining motor control through optimised stimulation — is frequently the most effective cognitive intervention available in DBS management.
Dr. Liu's clinical note: Patients and families often resist levodopa reduction — they associate the medication with symptom control and fear that reducing it will cause deterioration. The counterintuitive reality is that in a well-programmed STN-DBS patient, excess levodopa is often causing more harm than benefit. The stimulator is doing the motor work. The levodopa is adding cognitive side effects without adding motor benefit. Reducing the dose is not taking something away. It is removing an obstacle to cognitive clarity.
Outcomes and Follow-up
- UPDRS-III (on-stimulation, on-medication): Improved from 45 to 18 — 60% motor improvement
- Dyskinesia: Completely resolved — no peak-dose or diphasic dyskinesia at 3-month follow-up
- Gait freezing: FOG-Q score reduced by 50%; gait initiation and turning improved; no falls reported
- Cognition: MoCA recovered from 22 to 25; patient reports restored ability to write academic papers and conduct doctoral supervision sessions
- Speech: No speech arrest or hesitancy on new programme; verbal fluency testing improved
- Quality of life: PDQ-39 score significantly improved; returned to full-time lecturing; resumed international conference participation
- Mood: Mild depression stable on low-dose SSRI; no impulse control symptoms
Expert Commentary — Dr. Liu Zhengguo
1. STN vs GPi: Choosing the Right Target for the Right Patient
The choice between STN and GPi as the DBS target is the most consequential decision in Parkinson's surgical planning — and it cannot be made on motor criteria alone. STN-DBS offers superior levodopa reduction capacity, which is its primary cognitive protection mechanism in young patients: less levodopa means less dopaminergic cognitive side effects, less dyskinesia, and less impulse control risk. GPi-DBS offers greater cognitive safety in patients with pre-existing cognitive impairment, because GPi stimulation does not carry the same risk of verbal fluency and executive function decline. For this patient — young onset, high cognitive demands, good baseline cognition, and a strong preference to reduce medication — STN was the correct target. The key is not which target is better in general. It is which target is better for this specific patient at this specific stage of disease.
2. The Art of DBS Programming: Frequency, Directionality, and Interleaving
Standard 130Hz monopolar DBS programming is the starting point, not the destination. High-frequency stimulation suppresses neuronal firing throughout the STN — effective for tremor and rigidity, but potentially harmful for axial symptoms and cognitive networks that depend on STN associative and limbic circuits. Low-frequency stimulation (60–80Hz) modulates rather than suppresses STN activity, and accumulating evidence supports its superiority for gait freezing and postural instability. Directional current steering — using segmented electrode contacts to shape the electrical field — allows the clinician to target the dorsolateral motor STN while sparing the ventromedial limbic territory. Interleaving combines both strategies: different frequencies and amplitudes delivered to different contacts in alternating sequence, creating a composite electrical field that no single conventional programme can achieve. These are not experimental techniques. They are the current standard of care at experienced DBS centres.
3. Cognitive Preservation: The Drug-Stimulation Balance
Cognitive decline in long-standing DBS patients has three potential causes that must be systematically distinguished: disease progression (alpha-synuclein pathology spreading to cortical networks); stimulation-induced side effects from current spread to non-motor STN territories or adjacent structures; and medication-related cognitive effects from excess dopaminergic stimulation. Only the second and third are modifiable through programming and dose adjustment. In this case, the monopolar review identified stimulation-induced internal capsule spread as a primary contributor, and levodopa reduction addressed the medication component. The result — a three-point MoCA improvement — represents a clinically meaningful cognitive recovery that restored the patient's professional function. DBS programming is not just motor management. It is whole-brain management.
4. The Long-term DBS Patient: A Lifetime of Programming
Parkinson's disease is a progressive neurodegenerative condition. DBS does not stop the progression — it manages the motor complications of dopamine deficiency while the underlying pathology continues to evolve. As the disease progresses, the optimal stimulation parameters change: the therapeutic window narrows, new symptoms emerge, and the drug-stimulation balance requires continuous recalibration. A DBS patient implanted at age 50 will require expert programming support for the remainder of their life. At Ruijin Hospital, we have established a structured long-term follow-up protocol: three-monthly programming reviews in the first year, six-monthly thereafter, with annual neuropsychological assessment and multidisciplinary review involving neurology, functional neurosurgery, rehabilitation medicine, and neuropsychology. The surgery is one day. The programming is a lifetime.
How CMCS Shanghai Coordinated This Case
CMCS Shanghai supported Professor Hartley from initial inquiry through three-month post-reprogramming follow-up, including: pre-consultation review of DBS implant records, current programming parameters, UPDRS assessments, and neuropsychological test results; specialist referral to Dr. Liu Zhengguo at Ruijin Hospital's DBS Programming Centre; bilingual interpretation throughout all consultations and programming sessions; coordination of brain MRI for electrode position verification and neuropsychological assessment scheduling; real-time programming session updates to the patient's family; post-reprogramming monitoring with weekly symptom diary review and bilingual communication to the patient's neurologist in the United Kingdom; three-month follow-up UPDRS, MoCA, and FOG-Q assessment coordination with results translation; and long-term six-monthly programming review scheduling with direct liaison between Dr. Liu's team and the patient's overseas neurologist.
For international patients with Parkinson's disease and DBS requiring expert programming optimisation in Shanghai, Dr. Liu Zhengguo's team at Ruijin Hospital represents functional neurology expertise at the international frontier. CMCS ensures that expertise is accessible — in the patient's language, with their overseas physicians informed at every programming decision, and with continuity of care from initial consultation through lifelong DBS management.
This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.
0 則留言